Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Director departure
|
|
NeuroPace Inc (NPCE)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 10/04/2023 |
4
| ORBIMED ADVISORS LLC (10% Owner) has filed a Form 4 on NeuroPace Inc|
Txns:
| Sold 7,614 shares
@ $9.08, valued at
$69.1k
Sold 700 shares
@ $9.02, valued at
$6.3k
|
|
| 10/02/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 08/08/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 08/08/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/08/2023 |
8-K
| Quarterly results |
| 07/19/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 07/19/2023 |
3
| Form 3 - Initial statement of beneficial ownership of securities: |
| 07/19/2023 |
8-K
| Quarterly results |
| 06/28/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 06/12/2023 |
8-K
| Submission of Matters to a Vote of Security Holders Interactive Data |
| 05/04/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/04/2023 |
8-K
| Quarterly results |
| 04/25/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 04/25/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 04/25/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 04/13/2023 |
8-K
| Quarterly results |
| 03/02/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 03/02/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 03/02/2023 |
8-K
| Quarterly results |
| 02/22/2023 |
4
| Ridley Irina (Chief Legal Officer/Secretary) has filed a Form 4 on NeuroPace Inc|
Txns:
| Granted 80,000 shares
@ $0 |
|
| 02/22/2023 |
4
| Kuhn Rebecca (CFO) has filed a Form 4 on NeuroPace Inc|
Txns:
| Granted 80,000 shares
@ $0 |
|
| 02/22/2023 |
4
| Morrell Martha (Chief Medical Officer) has filed a Form 4 on NeuroPace Inc|
Txns:
| Granted 80,000 shares
@ $0 |
|
| 02/22/2023 |
4
| Favet Michael (CEO) has filed a Form 4 on NeuroPace Inc|
Txns:
| Granted 225,000 shares
@ $0 |
|
| 02/14/2023 |
SC 13G/A
| ORBIMED ADVISORS LLC reports a 16.1% stake in NeuroPace, Inc. |
| 02/14/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/10/2023 |
SC 13G
| MORGAN STANLEY reports a 8.8% stake in NeuroPace Inc |
| 02/09/2023 |
SC 13G
| FMR LLC reports a 5.8% stake in NEUROPACE INC |
| 01/09/2023 |
4
| Geiger Uri (Director) has filed a Form 4 on NeuroPace Inc|
Txns:
| Granted 120,521 options to buy
@ $1.535, valued at
$185k
|
|
| 01/09/2023 |
3
| Geiger Uri (Director) has filed a Form 3 on NeuroPace Inc |
| 01/09/2023 |
8-K
| Investor presentation |
| 11/23/2022 |
4
| Accelmed Partners II L.P. (10% Owner) has filed a Form 4 on NeuroPace Inc|
Txns:
| Bought 327,893 shares
@ $1.499, valued at
$491.5k
Bought 62,398 shares
@ $1.499, valued at
$93.5k
|
|
| 11/23/2022 |
SC 13D/A
| Accelmed Partners II L.P. reports a 17.8% stake in NeuroPace, Inc. |
| 11/23/2022 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 11/21/2022 |
SC 13D
| Accelmed Partners II L.P. reports a 16.2% stake in NeuroPace, Inc. |
|
|
|